Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds Robert Hale to board of directors

And Jeffrey Ubben resigns from the board
Valeant Robert Hale

Valeant has added Robert Hale, a partner at ValueAct Capital, to its board of directors.

Hale will be the fourth partner of ValueAct Capital, which holds approximately 4% of Valeant's outstanding stock, to serve on the Valeant board.

ValueAct Capital has been a shareholder in Valeant since 2006 and as a partner there Hale has worked closely with the board and management team since January 2011.

He said: “It's an exciting time for Valeant as the company positions itself for long-term growth and leadership in the pharmaceuticals and medical products industry.”

Meanwhile, Jeffrey Ubben, CEO and CIO of ValueAct Capital has resigned from the board.

He said: “I have had a wonderful experience serving as director of Valeant. While I no longer serve as a director, I look forward to working with Mike Pearson and the Valeant team as an interested shareholder on an on-going basis.”

Michael Pearson, chairman and CEO of Valeant, said: “We are delighted that we will continue to have board representation from ValueAct Capital.

“We have gotten to know Rob well over the past five years and are glad that he now serves as a director. Rob's strategic and financial expertise will add a valuable perspective to our board.”

Hale, prior to his current position, was principal of The Parthenon Group working at both their Boston and Mumbai offices.

27th August 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics